ArticleNature genetics2014
Human somatic cell mutagenesis creates genetically tractable sarcomas.
Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Systematic analysis of RNA-binding proteins identifies targetable therapeutic vulnerabilities in osteosarcoma.Nature communications · 2024Article
- The high-density lipoprotein binding protein HDLBP is an unusual RNA-binding protein with multiple roles in cancer and disease.RNA biology · 2024Review
- HDLBP binds ER-targeted mRNAs by multivalent interactions to promote protein synthesis of transmembrane and secreted proteins.Nature communications · 2022Article
- Association of mammographic density with blood DNA methylation.Epigenetics · 2022Article
- CRISPR: A new paradigm of theranostics.Nanomedicine : nanotechnology, biology, and medicine · 2021Review
- In vivo functional screening for systems-level integrative cancer genomics.Nature reviews. Cancer · 2020Review
- Ex Vivo Transposon-Mediated Genetic Screens for Cancer Gene Discovery.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Advances in functional genetic screening with transposons and CRISPR/Cas9 to illuminate cancer biology.Current opinion in genetics & development · 2018Review
- Modulating signaling networks by CRISPR/Cas9-mediated transposable element insertion.Current genetics · 2018Review
- Transposons As Tools for Functional Genomics in Vertebrate Models.Trends in genetics : TIG · 2017Review
- RNA Binding Protein Vigilin Collaborates with miRNAs To Regulate Gene Expression forG3 (Bethesda, Md.) · 2017Article
- Robust gene expression changes in the ganglia following subclinical reactivation in rhesus macaques infected with simian varicella virus.Journal of neurovirology · 2017Article
- The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation.Nature communications · 2016Article
- Systems Biology-Based Investigation of Cellular Antiviral Drug Targets Identified by Gene-Trap Insertional Mutagenesis.PLoS computational biology · 2016Article
- The utility of transposon mutagenesis for cancer studies in the era of genome editing.Genome biology · 2015Review
- Cancer gene discovery goes mobile.Nature genetics · 2014Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issuedIszvak, Zsuzsanna [corrected to Izsvák, Zsuzsanna
Authors and funding
19 authors at 5 institutions in 4 countries.
Funding
Abstract
Creating spontaneous yet genetically tractable human tumors from normal cells presents a fundamental challenge. Here we combined retroviral and transposon insertional mutagenesis to enable cancer gene discovery starting with human primary cells. We used lentiviruses to seed gain- and loss-of-function gene disruption elements, which were further deployed by Sleeping Beauty transposons throughout the genome of human bone explant mesenchymal cells. De novo tumors generated rapidly in this context were high-grade myxofibrosarcomas. Tumor insertion sites were enriched in recurrent somatic copy-number aberration regions from multiple cancer types and could be used to pinpoint new driver genes that sustain somatic alterations in patients. We identified HDLBP, which encodes the RNA-binding protein vigilin, as a candidate tumor suppressor deleted at 2q37.3 in greater than one out of ten tumors across multiple tissues of origin. Hybrid viral-transposon systems may accelerate the functional annotation of cancer genomes by enabling insertional mutagenesis screens in higher eukaryotes that are not amenable to germline transgenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.